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Purpose: To evaluate the morphological changes of the meibomian glands (MGs) using in vivo laser confocal microscopy
(CM) in dry eye (DE) patients with chronic graft-versus-host disease (cGVHD).
Methods: Seventeen eyes from 9 patients with a diagnosis of DE associated with cGVHD (DE/cGVHD group; 6 males,
3 females; median 50.5 years) and 16 eyes of 8 hematopoietic stem cell transplantation (HSCT) recipients without DE
(non-DE/non-cGVHD group; 5 males, 3 females; median 47.0 years) were enrolled. CM was used to investigate the MG
and MG acinar unit density (MGAUD), MG acinar longest diameter (MGALD), MG acinar shortest diameter (MGASD),
and the fibrosis grade. Clinical findings of the lid margin were obtained. Tear dynamics, ocular surface vital staining,
meibography, and MG expressibility were also examined. Data were compared between the 2 groups using the unpaired
t and Mann–Whitney tests.
Results: The mean MGAUD value was significantly lower in the DE/cGVHD group than in the non-DE/non-cGVHD
group (p=0.01, 57.8±38.3 glands/mm2, 88.8±26.6 glands/mm2, respectively), and the mean MGALD and MGASD were
significantly shorter in the DE/cGVHD group than in the non-DE/non-cGVHD group (p=0.0018, 37.3±24.4 μm and
60.4±11.8 μm, p=0.0106, 17.7±11.8 μm and 26.6±6.03 μm, respectively). The mean fibrosis grade was significantly higher
in the DE/cGVHD group than the non-DE/non-cGVHD group (p<0.0001, 1.39±0.71 grade, 0.06±0.25 grade, respectively).
Clinical findings in the lid margin, tear dynamics, and ocular surface findings were significantly worse in the DE/cGVHD
group than in the non-DE/non-cGVHD group.
Conclusions: CM clearly depicted the morphological changes of the MG in the DE/cGVHD group, and revealed the
severity of the meibomian gland dysfunction. Patients with severe DE after HSCT showed atrophic MG and excessive
fibrosis.
Meibomian  glands  (MGs)  are  sebaceous  glands
embedded  within  the  tarsal  plates.  Each  MG  comprises
multiple  acini  connected  by  a  long  common  central  duct
running throughout the entire length of the gland. Meibomian
glands  secrete  lipids  into  the  preocular  tear  film.  The
meibomian secretions form the outer layer of the tear film to
suppress evaporation and function as lubricants for the eyelids
during blinking [1]. Meibomian gland dysfunction (MGD) is
a  chronic,  diffuse  abnormality  of  the  meibomian  glands,
commonly characterized by terminal duct obstruction and/or
qualitative and quantitative changes in the glandular secretion.
This may result in alteration of the tear film, symptoms of eye
irritation, clinically apparent inflammation, and ocular surface
disease [2].
Chronic graft-versus-host disease (cGVHD) is a major
cause  of  morbidity  and  mortality  in  patients  undergoing
allogeneic hematopoietic stem cell transplantation (HSCT)
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for hematologic malignancies [3], and MGD is a second most
frequent  complication  of  ocular  cGVHD.  The  reported
prevalence of MGD in ocular cGVHD is 47.8% [4]. However,
to our knowledge, no report on the morphology of MG in cases
with cGVHD related dry eye (DE) has been published to date.
Existing methods for assessing MG status and function
include slit-lamp examination of the lid margins and ocular
surface epithelium, meibometry [5,6] (the assessment of the
volume  and  properties  of  the  meibum),  meibography
(evaluation  of  MG  morphology,  including  “drop-outs”)
[7-10], and in vivo laser confocal microscopy (CM) [11-13].
The last of these, CM is an emerging new imaging technique
that  can  noninvasively  detect  structural  changes  in  many
ocular surface diseases and anterior segment disorders. In this
study, we used CM to investigate the MG of patients with
cGVHD-associated DE and compared the results with those
from patients who did not develop DE after HSCT.
METHODS
Subjects and examinations: We had prospectively followed
up the HSCT patients at DE outpatient clinic and worked up
ocular findings before and after HSCT by communicating
with the KEIO BMT program transplant internist since 1996.
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2533Confocal microscopy was introduced to our outpatient clinic
in 2006. We started this case controlled study since 2010.
Between February 2010 and January 2011, we examined 17
patients for this study using CM. Among them, 9 patients had
newly developed DE after HSCT. The median period between
DE development and HSCT was 22.8 months (range; 8–72
months).  Seventeen  eyes  of  9  patients  who  had  cGVHD
related dry eye (DE/cGVHD group; 6 males and 3 females;
median age: 50.5 years; range: 38–57 years) and 16 eyes of 8
age- and gender-matched patients who did not develop DE
after  HSCT  (non-DE/non-cGVHD  group;  5  males  and  3
females; median age: 47.0 years; range: 26–62 years) were
analyzed. The demographic and clinical characteristics of the
DE/cGVHD  group  and  non-DE/non-cGVHD  group  are
shown in Table 1 and Table 2. There were no statistically
significant differences in interval between HSCT and CM
analysis between two groups. In addition, we divided the DE/
cGVHD group in this study into two groups with or without
systemic cGVHD (10 eyes of 5 cases, 7 eyes of 4 cases,
respectively)  to  examine  the  relationship  with  systemic
cGVHD. The reason why we subdivide the DE/cGVHD group
into two groups with or without systemic cGVHD is follows.
Conjunctival involvement in GVHD has been reported as a
marker for severe systemic GVHD [14]. In our previous study,
cGVHD  patients  with  conjunctival  fibrosis  had  systemic
complications and a poor prognosis following HSCT [15].
Therefore, we compared between DE/cGVHD group with and
without systemic involvement regarding as the meibomian
gland acinar unit density (MGAUD), the meibomian gland
acinar longest diameter (MGALD) and the meibomian gland
acinar shortest diameter (MGASD), and the fibrosis severity.
The  definition  of  systemic  GVHD  is  based  on
accompanied with or without clinically affected organs other
than the eyes as mentioned in the Table 1 and is according to
TABLE 1. DEMOGRAPHIC DATA FOR PATIENTS WITH CHRONIC GVHD RELATED DRY EYE (DE/CGVHD GROUP).
Case Age Gender HSCT
source
Underlying
disease
Interval
between
HSCT and
CM
analysis
(mo)
Interval
between
DE onset
and CM
analysis
(mo)
Interval
between
HSCT and
DE onset
(mo)
DE severity
level
CC Clinically
affected
cGVHD
organs
1 57 Male PBSC ML 17 1 16 3 - Eye, Skin
2 47 Male PBSC AML 19 6 13 4 + Eye, Skin,
Mouth, Liver
3 50 Male PBSC MM 12 1 11 4 + Eye, Mouth
4 47 Female BM MM 43 1 42 4 + Eye, Mouth
5 38 Female BM AML 12 0 12 2 - Eye
6 57 Male BM MDS 14 N.A. N.A. 3 + Eye
7 51 Male BM CML 120 48 72 2 - Eye
8 46 Female PBSC MM 116 108 8 2 - Eye
9 55 Male PBSC AML 25 17 8 4 + Eye, Skin
        HSCT=hematopoietic  stem  cell  transplantation;  CM=confocal  microscopy;  DE=dry  eye;  CC=cicatricial  change;
        PBSC=peripheral  blood  stem  cell;  BM=bone  marrow;  ML=malignant  lymphoma;  AML=acute  myeloid  leukemia;
        MM=multiple myeloma; MDS=myelodysplastic syndrome; CML=chronic myeloid leukemia; N.A.=not applicable.
TABLE 2. DEMOGRAPHIC DATA FOR HSCT RECIPIENTS WITHOUT DE (NON-DE/NON-CGVHD GROUP).
Case Age Gender HSCT source Underlying
disease
       Interval between HSCT and 
CM analysis (mo)
1 55 Male BM MM 20
2 28 Male BM ALL 168
3 52 Male PBSC CML 24
4 62 Male BM AML 72
5 26 Male BM MDS 26
6 61 Female BM AML 39
7 44 Female BM CML 199
8 48 Female BM AML 177
        HSCT=hematopoietic stem cell transplantation; CM=confocal microscopy; DE=dry eye; PBSC=peripheral blood stem cell;
        BM=bone marrow; MM=multiple myeloma; ALL=acute lymphocytic leukemia; CML=chronic myeloid leukemia; AML=acute
        myeloid leukemia; MDS=myelodysplastic syndrome.
Molecular Vision 2011; 17:2533-2543 <http://www.molvis.org/molvis/v17/a274> © 2011 Molecular Vision
2534a previous report [16]. We excluded one eye from a patient
(Case 5; Table 1) in the DE/cGVHD group because of phthisis
from all of the analysis of this study. Topical eye drops,
including artificial tears, vitamin A, and autologous serum
drops, were instilled five times a day, immediately after the
diagnosis of DE following HSCT.
We used the global diagnostic criteria for DE, which is
based on the recommendation of the 2007 International Dry
Eye Workshop Report [17]. Patients who had a history of
surgical lacrimal punctal occlusion, allergies, contact lens use,
glaucoma eye drop use, or other ocular surgery, including
refractive surgery or radiation to the eyes, were excluded, as
were  patients  with  infectious  blepharitis,  blink  disorders,
disorders of the lid aperture or lid/globe congruity, or other
ocular surface disorders. In addition, patients with trachoma
and  ocular  cicatricial  pemphigoid  were  excluded.  The
research procedures in this study followed the tenets of the
Declaration of Helsinki Principles, and informed consent was
obtained from all subjects. IRB/Ethics Committee approval at
Keio University was obtained for this study.
Ocular  surface  vital  staining:  The  fluorescein  and  Rose-
Bengal staining scores for the ocular surface were obtained
using the double vital staining method [18]. Both stains were
scored on a scale of 0–9 [18,19]. The van Bijsterveld scoring
system was used for the Rose-Bengal staining. Briefly, the
ocular  surface  was  divided  into  three  zones:  nasal
conjunctival,  corneal,  and  temporal  conjunctival  areas.  A
score of 0–3 points was used for each zone, with a minimum
possible  score  of  0  and  a  maximum  of  9  points.  Scarce
punctuate staining was given 1 point, denser staining that did
not cover the entire zone was given 2 points, and Rose-Bengal
staining over the entire zone was given 3 points. For the
fluorescein staining, the cornea was divided into three equal
zones (upper, middle, and lower). A score of 0 to 3 points was
used  for  each  zone,  as  with  the  Rose-Bengal  stain.  The
presence of scarce staining in a zone was scored as 1 point;
frequent puncta not covering the entire zone as 2 points, and
punctuate staining covering the entire zone as 3 points.
Meibomian gland secretions: The expression of meibomian
secretion (meibum) was graded as described by Shimazaki et
al. [10]. Briefly, to assess obstruction of the meibomian gland
orifices, digital pressure was applied on the upper tarsus, and
the expression of meibomian secretion (meibum) was scored
semiquantitatively as follows: grade 0, clear meibum, easily
expressed;  grade  1,  cloudy  meibum,  expressed  with  mild
pressure; grade 2, cloudy meibum, expressed with more than
moderate pressure; and grade 3, no meibum expressed even
under hard pressure. Two independent investigators (Y.B. or
Y.O.)  pressed  gently  on  the  upper  eyelids  to  express  the
meibomian lipids.
Meibomian  gland  dropout  grades  (meibography):  The
meibography apparatus was composed of a slit lamp (RO
5000; Rodenstock, Munich, Germany) and an infrared charge-
coupled device video camera (XC-EI50; Sony, Tokyo, Japan)
[7-9].The MG structure was observed on the under side of the
upper and lower eyelids, by everting the lids manually. The
degree of MG drop out was scored as reported previously
(Shimazaki grading): 0, no gland drop out; 1, drop out with
loss of less than half of the glandular structures; and 2, drop
out with loss of more than half of the glandular structures
[20]. We obtained the values as the average of the upper and
lower grades.
Lid margin abnormalities: The presence or absence of four
parameters  in  lid  margin  abnormalities  (i.e.,  irregular  lid
margin;  absence=0  or  presence=1,  vascular  engorgement;
absence=0 or presence=1, plugged MG orifices; absence=0 or
presence=1  and  anterior  or  posterior  replacement  of  the
mucocutaneous  junction,  absence=0  or  presence=1)  were
scored from 0 through 4, according to the number of these
abnormalities  using  slit  lamp  examination  [6,7,21-23].
Therefore, all four parameters for lid margin abnormality were
present, the maximum score was given as 4.
Tear  function  test:  Tear  film  break  up  time  (TBUT)  was
measured three times, and the median value was calculated
[18]. The Schirmer’s test was performed using standard strips
(Showa Yakuhin Kako Co. Ltd., Tokyo, Japan) placed in the
lower conjunctival sac for 5 min without anesthesia.
In vivo laser confocal microscopy: In vivo laser CM was
performed on all subjects, using a newly developed confocal
microscope, the Heidelberg Retina Tomograph II-Rostock
Cornea  Module  (Heidelberg  Engineering  GmbH,
Dossenheim,  Germany),  as  described  previously  [11-13].
Briefly, after the lower eyelid was everted, the center of the
Tomo-Cap was placed onto the palpebral conjunctiva, and the
MGs were scanned while moving the applanating lens. To
evaluate the morphologic changes in the MG, we measured
the acinar unit density, the longest and the shortest acinar unit
diameters, as described previously [11-13]. In addition, we
devised one new parameter, the fibrosis severity. The degree
of fibrosis severity was scored as follows: grade 0, no fibrosis;
grade 1, fibrosis in less than half of the lower eyelid; grade 2,
fibrosis in more than half of the lower eyelid. Clearly visible
acinar units in a 400×400-μm frame were all counted, and the
acinar density was described as the number of units per square
millimeter. We calculated the longest and shortest diameters
in  μm  using  ImageJ  software  (Java  software  program
developed  by  the  National  Institutes  of  Health,  Bethesda,
MD). Three randomized nonoverlapping high-quality digital
images  of  the  lower  eyelid  were  used  for  the  CM-based
assessments. We calculated the mean MGAUD, MGALD,
MGASD,  and  the  fibrosis  grade  from  three  randomized
nonoverlapping images.
Diagnosis of dry eye (DE): The diagnosis and classification
of  DE  disease  based  on  its  severity  was  performed  as
recommended by the 2007 International Dry Eye Workshop
Report. Dry eye is a multifactorial disease of the tears and
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2535ocular surface that results in symptoms of discomfort, visual
disturbance, and tear film instability with potential damage to
the ocular surface. It is accompanied by increased osmolarity
of the tear film and inflammation of the ocular surface [17].
Diagnosis of cGVHD: All the patients in our study fulfilled
the revised consensus criteria for cGVHD [24]. Briefly, a
diagnosis of cGVHD requires the following: (1) a distinction
from acute GVHD, (2) the presence of at least one distinctive
manifestation (e.g., keratoconjunctivitis sicca) confirmed by
pertinent biopsy or other relevant tests (e.g., Schirmer’s test)
in the same or other organs, and (3) the exclusion of other
possible diagnoses.
Conjunctival fibrosis: We diagnosed conjunctival fibrosis in
patients who had subconjunctival fibrosis, fornix shortening,
symblepharon,  and/or  ankyloblepharon  [14,25].  We
evaluated these findings by using slit-lamp microscopy during
a routine examination.
Statistical analyses: The unpaired t-test for TBUT, Schirmer
test  value,  MGAUD,  MGALD,  and  MGASD  and
nonparametric  Mann–Whitney  test  for  fluoresecein  score,
Rose-Bengal  score,  MG  expressibility,  meibography,  lid
margin abnormality and fibrosis grade were used to compare
between two groups (the DE/cGVHD group versus the non-
DE/non-cGVHD  group;  Table  3  and  Table  4).  We  also
compared between the DE/cGVHD group with and without
systemic cGVHD using this test (Table 5). In addition, we
compared between the DE/cGVHD group without systemic
cGVHD and the non-DE/non-cGVHD group (Table 6). A p
value  of  0.05  was  considered  statistically  significant.
GraphPad Instat (GraphPad Software, San Diego, CA) was
used for the statistical analyses.
RESULTS
Data on tear function and ocular surface evaluation: The
mean value of tear function test including TBUT and Schirmer
TABLE 3. COMPARISON OF OCULAR SURFACE/TEAR DYNAMICS BETWEEN THE DE/CGVHD GROUP AND NON-DE/NON-CGVHD GROUP.
Examinations DE/cGVHD group Non-DE/non-cGVHD group p-value
F (points) 4.88±3.06 0.38±0.62 <0.0001‡
RB (points) 5.06±2.41 0.13±0.34 <0.0001‡
MG expressibility (points) 2.47±0.92 0.75±0.93 <0.0001‡
Meibography (grade) 1.41±0.80 0.50±0.52 0.0014‡
Lid margin (grade) 2.94±1.35 0.38±0.72 <0.0001‡
TBUT (seconds) 2.35±1.90 6.94±3.04 <0.0001*
Schirmer (mm) 1.64±1.21 5.80±2.30 <0.0001*
         DE=dry eye; cGVHD=chronic graft-versus-host disease; F=fluorescein score; RB=Rose-Bengal score; MG=meibomian gland;
         TBUT=tear film break up time; *=Unpaired t-test, ‡=Mann–Whitney test.
TABLE 4. COMPARISON OF MEIBOMIAN GLANDS BETWEEN THE DE/CGVHD GROUP AND NON-DE/NON-CGVHD GROUP USING IN VIVO LASER
CONFOCAL MICROSCOPY.
Examinations DE/cGVHD group Non-DE/non-cGVHD group p-value
MGAUD (glands/mm2) 57.8±38.3 88.8±26.6 0.01*
MGALD (μm) 37.3±24.4 60.4±11.8 0.0018*
MGASD (μm) 17.7±11.8 26.6±6.03 0.0106*
Fibrosis (grade) 1.39±0.71 0.06±0.25 <0.0001‡
         DE=dry eye; cGVHD=chronic graft-versus-host disease; MGAUD=meibomian gland acinar unit density; MGALD=meibomian
         gland acinar longest diameter; MGASD=meibomian gland acinar shortest diameter; *=Unpaired t-test; ‡=Mann–Whitney test.
TABLE 5. COMPARISON OF MEIBOMIAN GLANDS BETWEEN THE DE/CGVHD GROUP WITH SYSTEMIC CGVHD AND THE DE/CGVHD GROUP WITHOUT SYSTEMIC CGVHD
USING IN VIVO CONFOCAL MICROSCOPY.
Examinations DE/cGVHD group with systemic 
cGVHD (10 eyes, 5 cases)
DE/cGVHD group without systemic 
cGVHD (7 eyes, 4 cases)
p-value
MGAUD (glands/mm2) 38.4±30.0 85.5±32.3 0.0097*
MGALD (μm) 19.3±7.31 63.0±14.2 < 0.0001*
MGASD (μm) 10.7±4.33 27.6±12.0 0.0009*
Fibrosis (grade) 1.87±0.23 0.71±0.59 0.0007‡
        DE=dry eye; cGVHD=chronic graft-versus-host disease; MGAUD=meibomian gland acinar unit density; MGALD=meibomian
        gland acinar longest diameter; MGASD=meibomian gland acinar shortest diameter; *=Unpaired t-test; ‡=Mann–Whitney test.
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2536test and ocular surface staining scores including Rose-Bengal
and fluoresecein were significantly worse in the DE/cGVHD
group  than  in  the  non-DE/non-cGVHD  group  (p<0.0001;
Table 3).
Meibomian gland secretions: The mean MG expressibility
score was significantly higher (grade 2.47±0.92 grade) in the
DE/cGVHD group than in the non-DE/non-cGVHD group
(grade 0.75±0.93 grade; p<0.0001; Table 3).
Meibography: The numerous meibomian gland dropouts were
observed by using noncontact infrared meibography from a
57-year-old male (Case 1; Table 1) in the DE/cGVHD group
(Figure 1A,C). In contrast, there was no loss of MG in a 28-
year old male (Case 2; Table 2) who did not develop DE after
HSCT in the non-DE/non-cGVHD group (Figure 1B,D). The
mean  meibomian  gland  dropout  grade  was  significantly
higher (1.41±0.80 grade) in the DE/cGVHD group than in the
non-DE/non-cGVHD  group  (0.50±0.52  grade;  p=0.0014;
Table 3).
Lid margin abnormalities: Slit lamp examination revealed
irregular lid margin, vascular engorgement, plugging of MG
orifices  and  posterior  replacement  of  the  mucocutaneous
junction  from  a  representative  50-year-old  male  (Case  3;
Table 1) in the DE/cGVHD group (Figure 2).
The  mean  lid  margin  score  was  significantly  higher
(2.94±1.35 grade) in the DE/cGVHD group than in the non-
DE/non-cGVHD group (0.38±0.72 grade; p<0.0001; Table
3).
In vivo laser confocal microscopy: CM clearly depicted the
glandular acinar units in the non-DE/non-cGVHD group. The
CM images also revealed morphologic alterations in the DE/
cGVHD group, including atrophic MG and extensive fibrosis.
The confocal microscopic images observed at the onset of DE
related to cGVHD from a representative 47-year-old male
TABLE 6. COMPARISON OF MEIBOMIAN GLANDS ASSESSED BY IN VIVO LASER CONFOCAL MICROSCOPY, MG EXPRESSIBILITY, MEIBOGRAPHY AND LID MARGIN
ABNORMALITY BETWEEN THE DE/CGVHD GROUP WITHOUT SYSTEMIC CGVHD AND NON-DE/NON-CGVHD GROUP.
Examinations DE/cGVHD group without systemic 
cGVHD (7 eyes, 4 cases)
non-DE/non-cGVHD 
group (16 eyes, 8 cases)
p-value
MGAUD (glands/mm2) 85.3±32.3 88.8±26.6 0.8021
MGALD (μm) 63.0±14.2 60.4±11.8 0.65
MGASD (μm) 27.6±12.0 26.6±6.03 0.7888
Fibrosis (grade) 0.71±0.59 0.06±0.25 0.0016‡
MG expressibility (points) 2.20±1.10 0.75±0.93 0.0189‡
Meibography (grade) 1.14±0.69 0.50±0.52 0.0399‡
Lid margin (grade) 2.0±1.41 0.38±0.72 0.0019‡
         DE=dry eye; cGVHD=chronic graft-versus-host disease; MGAUD=meibomian gland acinar unit density; MGALD=meibomian
         gland acinar longest diameter; MGASD=meibomian gland acinar shortest diameter; MG=meibomian gland; ‡=Mann–Whitney
         test.
Figure  1.  Meibomian  gland  images
observed  by  noncontact  infrared
meibography. A, C: DE/cGVHD group,
57 year-old male (Case 1; Table1). Note
the  numerous  meibomian  gland
dropouts. B, D: Non-DE/Non-cGVHD
group,  28-year-old  male  (Case  2;
Table2) No loss of meibomian glands
was observed in the patient who did not
develop  DE  after  HSCT.  UL=Upper,
Left, LL=Lower, Left.
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2537(Case  2;  Table  1)  in  the  DE/cGVHD  group  showed  the
excessive  fibrosis  around  the  atrophic  glands  and  the
moderate infiltration of inflammatory cells (Figure 3B,D).
Seventeen months after the onset of DE related to cGVHD
showed the excessive fibrosis around the atrophic glands and
the  mild  infiltration  of  inflammatory  cells  from  a
representative 55-year-old male patient (Case 9; Table 1) in
the DE/cGVHD group (Figure 4). In contrast, the confocal
microscopic images from a representative 61-year-old female
(Case 6; Table 2) in non-DE/non-cGVHD group showed the
presence of numerous and compact acinar units (Figure 5).
The mean MGAUD was 57.8±38.3 gland/mm2 in the DE/
cGVHD group, which was significantly lower than in the non-
DE/non-cGVHD group (88.8±26.6 gland/mm2, p=0.01). The
MGALD was significantly shorter in the DE/cGVHD group
than in the non-DE/non-cGVHD group (37.3±24.4 μm versus
60.4±11.8 μm, p<0.0018). In addition, the MGASD was also
significantly shorter in the DE-cGVHD group than in the non-
DE/non-cGVHD group (17.7±11.8 μm versus 26.6±6.03 μm,
p=0.0106).  The  fibrosis  grade  was  significantly  higher
(1.39±0.71 grade) in the DE/cGVHD group than in the non-
DE/non-cGVHD group (0.06±0.25 grade, p<0.0001, Table 4).
When  the  DE/cGVHD  group  was  subdivided  into
patients with systemic cGVHD and patients with only ocular
cGVHD, the mean MGAUD value was significantly lower in
the patients with systemic cGVHD (38.4±30.0 gland/mm2)
than in those without it (85.5±32.3 gland/mm2, p=0.0097).
The MGALD was significantly shorter in the patients with
systemic  cGVHD  than  in  those  without  systemic  GVHD
(19.3±7.31 μm versus 63.0±14.2μm, p<0.0001). In addition,
the MGASD was also significantly shorter in the patients with
systemic  cGVHD  than  in  those  without  systemic  GVHD
(10.7±4.33 μm versus 27.6±12.0 μm, p=0.0009; Table 5). The
fibrosis grade was significantly higher (1.87±0.23 grade) in
the DE/cGVHD group with systemic cGVHD than in those
with  non-systemic  cGVHD  (0.71±0.59  grade,  p=0.0007;
Table 5).
The value of the MGAUD, the MGALD and the MGASD
in  the  DE/cGVHD  group  without  systemic  cGVHD  was
similar to the value of those in the non-DE/non-cGVHD group
(Table 6).
DISCUSSION
To the authors’ knowledge, this is the first comprehensive
study to conduct a morphologic assessment of the MG in DE
patients with cGVHD after HSCT using in vivo CM. We
found  that  in  patients  with  cGVHD  related  DE,  the  MG
showed severe abnormalities, as assessed by in vivo CM. The
characteristics of MGD in cGVHD are that atrophic MG and
excessive fibrosis assessed by CM accumulated the almost
entire MG including acini, ductules, main ducts, and orifices.
In addition, MGD in cGVHD progressed rapidly shortly after
the onset of DE [4].
MGs  are  specialized  sebaceous  glands.  It  has  been
reported that the bulge of hair follicles located below the
opening of the sebaceous duct is destroyed by donor T cells
in cGVHD skin lesions [26]. Blisters formation of the mucous
membrane due to pseudomembrane or donor lymphocyte and/
or donor macrophages attack to the recipient epithelia can
occur  in  ocular  cGVHD  [27].  Similar  pathogenic  process
might contribute recipient MG epithelia of orifices, ducts,
ductule or acini, leading to secondary fibrotic spontaneous
occlusion and the adhesion of various structures of meibomian
glands.
Figure 2. Anterior slit lamp photograph;
DE/cGVHD  group,  50-year-old  male
(Case 3; Table 1). The anterior slit lamp
photograph  showing  irregular  lid
margin,  vascular  engorgement,
plugging of MG orifices, and posterior
replacement  of  the  mucocutaneous
junction.
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2538Previous studies showed that tissue atrophy and excessive
fibrosis are prominent histological features of salivary gland
and lacrimal gland in cGVHD [28-30]. We have reported T
cells  and  fibroblasts  in  lacrimal  gland  cGVHD  patients
primarily are activated in the periductal area, and contribute
to  the  pathogenic  fibrosis  [30].  In  addition,  activated
fibroblasts  derived  from  epithelia  via  local  epithelial
mesenchymal transition [31] or arise from bone marrow under
inflammatory  stress  [29]  might  contribute  to  excessive
fibrosis around the MG ducts. Therefore, we proposed that
extensive  MG  fibrosis  were  exacerbated  by  inflammation
under  inflammatory  cells  and  fibroblasts  interaction  and
subsequent activation leading to excessive accumulation of
extracellar matrix and pathogenic fibrosis in meibomian gland
microenvironment.  These  factors  are  considered  to  be
characteristic in cGVHD in comparison with other MGD.
Aging  may  also  exacerbate  the  periglandular
inflammation and fibrosis. Because it is reported that MGD is
facilitated by aging [7,22], median age is 50.5 years in our
cases  may  have  a  potential  to  develop  MGD  by  aging.
However,  MGD  parameter  of  age-matched  non-GVHD
patients was statistically better, the possibility influenced by
aging  is  unlikely.  Therefore,  we  propose  that  our  results
obtained this study is associated with cGVHD.
Because we prospectively followed the HSCT recipients
since 1996, we could observe the MG at the onset of DE
related to cGVHD. Excessive fibrosis was detectable by in
vivo  CM  shortly  after  the  onset  of  cGVHD-related  DE.
Previous  reports  have  found  that  the  MGALD
(86.3±18.9  μm)  and  MGASD  (34.8±9.2  μm)  were  both
significantly  larger  in  MGD  patients  than  in  controls
(56.3±10.4  μm,  p<0.0001,  and  17.4±4.2  μm,  p<0.0001,
respectively) [11,12]. In age related MGD, the mechanism of
morphologic  changes  in  MG  was  suggested  that
hyperkeratinization  of  the  ductal  epithelium,  shedding  of
keratinized  material  into  the  glandular  ducts  leading  to
orificial  obstructions,  and  eventual  cystic  dilatation  and
atrophy [32].
Recently, morphological changes of MG in Sjogren’s
syndrome (SS) have been reported using CM. In this study,
MGALD  has  been  reported  53±31μm  in  primary  SS  and
70±42 μm in secondary SS. These values are longer than that
of cGVHD obtained in this study [33]. In cGVHD, tissue
atrophy and excessive fibrosis were prominent histological
Figure  3.  Meibomian  gland  of  DE/
cGVHD patients images observed by in
vivo laser confocal microscopy. A, C:
DE/cGVHD group, 47-year-old female
(Case  4;  Table1).  B,  D:  DE/cGVHD
group, 47-year-old male (Case 2; Table
1). The images observed at the onset of
DE  related  to  cGVHD.  Note  the
excessive fibrosis around the atrophic
glands and the moderate infiltration of
inflammatory  cells  in  the  dry  eye
patients  with  cGVHD.  RL=Right,
Lower, LL=Left, Lower.
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2539features, may explain the disaccordance of our results with
those of previous reports.
Interestingly, we also found that the mean MGAUD in
the DE/cGVHD group with systemic cGVHD was lower than
in the DE/cGVHD group without systemic cGVHD, and the
mean MGALD and MGASD were shorter. These patients had
severe DE, and 5 out of 9 HSCT recipients (55.6%) showed
excessive fibrosis of the MG. The MG of patients with DE but
without systemic cGVHD resembled those of the non-DE
group. A previous report showed that cGVHD patients with
conjunctival fibrosis had systemic complications and a poor
prognosis following HSCT [14]. Our results suggested that
the MG of DE/non-systemic cGVHD resembled those of the
non-DE group. In other words, these findings suggested that
dry eye related to cGVHD did not affected meibomian gland
alterations. Although we analyzed a small number of patients,
there is a statistically significant difference for fibrosis grades
between the MG of DE/non-systemic cGVHD and those of
the non-DE group. There is a possibility that fibrosis rather
than dry eye itself may play a central role for the development
of the MGD in cGVHD, similar to cGVHD lacrimal gland
pathology. Our previous study have insisted that fibrosis is a
leading cause of dry eye related to cGVHD and even in the
early  course  of  the  diseases  [34].  In  cGVHD,  there  is  a
possibility that fibrosis is a primary event and consequently
leads to MGD and dry eye separately.
Taken together, we believe that the cause of MGD in
cGVHD is multifactorial and multistep. Destruction of the
ductal epithelia due to lymphocyte infiltration, slouging of
epithelial cells due to lymphocyte attack or pseudomembrane
formation,  and  subsequent  excessive  fibrosis  around  the
orifice, ducts, ductules, and acini of the MG, may explain for
the development of MGD after HSCT.
Although  further  studies  are  necessary,  our  study
suggests that CM findings on the MG in HSCT recipients may
be useful for evaluating their likely progression to MGD. In
this study, we conducted CM for the lower lid. It is difficult
for us to evaluate the upper eyelid margin, whereas the lower
one  is  easily  positioned  and  examined.  A  confocal
examination require a prolonged contact for several minutes
between  instrument  and  examined  inverted  upper  eye  lid
tarsal conjunctiva, which can be uncomfortable for the patient
during examination as reported previously [33]. Moreover the
instrument  has  a  space  fix  orientation,  so  it  requires  the
polymethacrylate sterile cap (Tomo-cap) face, leads to more
difficult to evaluate the upper lid meibomian glands. It is
necessary for us to develop the methods as for examining
upper  tarsal  conjunctiva  more  comfortable  for  further
evaluating the entire MG morphology.
We used topical immunosuppressants when the patients
were tapering off their systemic immunosuppressive therapy
for cGVHD related dry eye [35]. Furthermore, our group
reported that topical tranilast for the treatment of early fibrosis
may effectively retard cGVHD related DE progression when
given in the early stages [36]. Therefore, early use of topical
immunosuppressant and anti-fibrotic intervention might be
useful  strategy  for  preventing  or  retarding  the  MGD
associated fibrosis in cGVHD.
In summary, we conducted a morphometric assessment
of the MG in DE patients with cGVHD using in vivo laser
CM.  CM  clearly  demonstrated  morphological  changes
including  inflammatory  cell  infiltration  and  excessive
fibrosis, even in early stage, in the MG of DE patients with
Figure  4.  Meibomian  gland  of  DE/
cGVHD patient images observed by in
vivo  laser  confocal  microscopy.  DE/
cGVHD group, 55-year-old male (Case
9; Table 1). The images observed after
17 months on the onset of DE related to
cGVHD.  Note  the  excessive  fibrosis
around the atrophic glands and the mild
infiltration of inflammatory cells in the
dry  eye  patients  with  cGVHD.
LL=Lower, Left.
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2540cGVHD. Our results also suggested that MGD may allow us
to diagnose severe DE and cGVHD early in the course of the
disease. Early detection of MGD could be important, because
it could signal a progression to severe DE, and extensive
cGVHD,  which  can  lead  to  blindness  and  become  life-
threatening.
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